2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Motor Activity
20
Polycystic Ovary Syndrome
10
Prostatic Neoplasms
7
Breast Neoplasms
6
Neoplasms
5
Colorectal Neoplasms
4
Insulin Resistance
3
Lung Neoplasms
2
Fatigue
2
Esophageal Neoplasms
2
Cardiotoxicity
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Primary Dysautonomias
1
Pediatric Brain Tumor
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma, Follicular
1
Lupus Erythematosus, Systemic
1
Inflammation
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Disease
1
Diabetes Mellitus, Type 1
1
Chemotherapy-Related Cognitive Impairment
1
Cardiovascular Diseases
1
Interventions
Nivolumab
2
sotrovimab
1
gusacitinib
1
ciclesonide
1
cabozantinib
1
anifrolumab
1
Standard of Care
1
Specimen Handling
1
Procalcitonin
1
Practice Guidelines as Topic
1
Platinum Compounds
1
Niclosamide
1
Methods
1
Ipilimumab
1
Interviews as Topic
1
Immune Checkpoint Inhibitors
1
High-Intensity Interval Training
1
Exercise
1
Educational Status
1
Early Intervention, Educational
1
Cholecalciferol
1
CTLA-4 Antigen
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lupus Erythematosus, Systemic
×
High-Intensity Interval Training
×
Clear all
NCT05478018
2025-09-09
LUPEX
Rigshospitalet, Denmark
Phase NA
Completed
55 enrolled